Psychiatry 2008 - September 2008 - (Page 54)

[journal watch] literature to explore pharmacological treatments of anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and posttraumatic stress disorder), both commonly used medications and agents such as anticonvulsants and atypical antipsychotics. PMID: 18704983 Effectiveness of benzodiazepines: do they work or not? Lader M. Expert Rev Neurother. 2008 Aug;8(8):1189-1191. Synopsis: In this review of the efficacy, effectiveness and dropout for adverse effects related to use of benzodiazepines, the author found no convincing evidence of shortterm effectiveness while adverse effects were 1.5-times more frequent in drug-treated versus placebo patients. The author presents explanations for these results, illustrates changes in diagnostic criteria over time, and discusses lack of accepted methods of assessing estimates of effectiveness in clinical practice. PMID: 18671662 schizoaffective disorder. Based on the results, they conclude that sustained D(2) occupancy at or above the accepted threshold with acute clinical response may not be necessary to maintain response, a finding that they conclude has clinical implications for antipsychotic dosing and development. PMID: 18642974 Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Llorca PM, Sacchetti E, Lloyd K, et al. Int J Clin Pharmacol Ther. 2008 Jan;46(1):14-22. Synopsis: Researchers monitored long-term symptomatic tolerability and remission in patients with stable but suboptimally treated psychoses after switching to risperidone long-acting injectable (RLAI) in 529 patients who were followed for up to 18 months. Based on the results, authors conclude that (1) RLAI is safe during longterm treatment up to 18 months in adults requiring antipsychotics, (2) conversion to RLAI resulted in improved symptom control, and (3) most patients achieved and maintained a sustained remission of 6 months or more after conversion to RLAI. PMID: 18218293 Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Möller HJ. Drugs. 2007;67(11):1541-1166. Review. Synopsis: Author reviews longacting injectable risperidone for the treatment of schizophrenia, including background on depot formulations of conventional antipsychotics, and a discussion of two 12-week, double-blind, randomized, phase III studies and one open-label, 12-month study. Based on the findings, author concludes that the safety and tolerability of the long-term formulation of risperidone are comparable to those of the oral formulation, the local tolerability at the injection site is good, and that consideration for a broader use of the long-term formulation is warranted. PMID: 17661527 Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. Chue P, Emsley R. CNS Drugs. 2007;21(6):441-8. Review. Comment in: CNS Drugs. 2008;22(3):257-8. Synopsis: In this article, authors discuss use of the long-acting formulation of risperidone for treatment of schizophrenia, and argue that long-acting risperidone should be considered for firstepisode patients who often experience early treatment discontinuation and poor treatment adherence. PMID: 17521224 Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. Emsley R, Medori R, Koen L, et al. J Clin Psychopharmacol. 2008 Apr;28(2):210-213. Synopsis: Researchers analyzed results of treating 50 patients, aged 15 to 43 years, newly diagnosedwith schizophreniform disorder or schizophrenia, with risperidone long-acting injection (RLAI) to determine whether the long-acting formulation is safe and effective in the treatment of recent-onset 54 RISPERIDONE LONG-ACTING INJECTIONS TO TREAT SCHIZOPHRENIA Monthly administration of longacting injectable risperidone and striatal dopamine D(2) receptor occupancy for the management of schizophrenia. Uchida H, Mamo DC, Kapur S, et al. J Clin Psychiatry. 2008 Jul 15:e1e6. [Epub ahead of print] Synopsis: Researchers used positron emission tomography to study the striatal dopamine D(2) binding of long-acting risperidone administered intramuscularly once a month in seven patients diagnosed with schizophrenia or 54 Psychiatry 2008 [ S E P T E M B E R ]

Table of Contents Feed for the Digital Edition of Psychiatry 2008 - September 2008

Psychiatry 2008 - September 2008 Editor’s Message Editorial Advisory Board Contents Psych Rx Letters to the Editor Use of Benzodiazepines in the Treatment of Anxiety Functional Neurosurgery in the Treatment of Severe Obsessive Compulsive Disorder and Major Depression: Overview of Disease Circuits and Therapeutic Targeting for the Clinician Treatment of Comorbid Adolescent Cannabis Use and Major Depressive Disorder Risperidone Long-acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia Alcohol/Substance Misuse and Treatment Nonadherence: Fatal Attraction Transforming the Psychiatric Inpatient Unit from Short-term Pseudo-asylum Care to State-of-the-art Treatment Setting Journal Watch Classified Advertising Information for Authors

Psychiatry 2008 - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.